Exhibit 99.1

LIFECORE BIOMEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND FISCAL YEAR ENDED JUNE 30, 2006

Sales Increase 19%; Pro-Forma Profits Up 70%

CHASKA, MN. – August 10, 2006 – LIFECORE BIOMEDICAL, INC. (Nasdaq: LCBM) today reported record net sales of $17.7 million in the fourth quarter ended June 30, 2006, an increase of 19% over net sales of $14.9 million in the fourth quarter of fiscal year 2005.

Fiscal fourth quarter GAAP net income of $2,411,000, or $.18 per diluted share, was posted for the quarter compared to GAAP net income of $11,744,000, or $.87 per diluted share, in the quarter ended June 30, 2005. The fourth quarter of last fiscal year was significantly impacted by the release of the deferred tax valuation allowance in the net amount of $10,205,000, after deducting income tax expense of $1,717,000. Excluding the effect of these tax adjustments, pro-forma fiscal 2005 fourth quarter net income was $1,539,000, or $.11 per diluted share, after applying an effective tax rate of 33.3%. Fiscal 2006 fourth quarter results include expenses for stock options in the amount of $211,000 and income tax expense of $1,586,000 at an effective rate of 39.7%. Pro-forma net income for the fourth quarter of fiscal 2006 was $2,622,000, or $.19 per diluted share, when the stock option expense is excluded. Pro-forma results reflected a 70% increase in net income for the fourth quarter. (See Disclosure of Pro-Forma Information and Reconciliation of GAAP Net Income to Pro-Forma Net Income Information later in this press release.)

For its fiscal year ended June 30, 2006, Lifecore had record net sales of $63.1 million, an increase of 13% over the $55.7 million reported in fiscal year 2005. Foreign currency translation comparisons decreased fiscal 2006 sales by $422,000 compared to fiscal 2005.

Fiscal 2006 GAAP net income was $7,040,000, or $.52 per diluted share, compared to fiscal 2005 GAAP net income of $17,511,000, or $1.31 per diluted share, which includes the previously mentioned non-recurring tax benefit. Excluding the effect of the tax benefit, pro-forma fiscal 2005 net income was $5,589,000, or $.42 per diluted share, after applying an effective tax rate of 33.3%. Fiscal 2006 results include expenses for stock options in the amount of $844,000 and income tax expense of $4,380,000 at an annual effective rate of 38.4%. Pro-forma net income for fiscal 2006 was $7,884,000, or $.58 per diluted share, when the stock option expense is excluded. Pro-forma results reflected a 41% increase in net income for the fiscal year. (See Disclosure of Pro-Forma Information and Reconciliation of GAAP Net Income to Pro-Forma Net Income Information later in this press release.)

“We posted records in both sales and pro-forma net income for the second year in a row,” said Dennis J. Allingham, President and CEO. “We are obviously pleased with the results and I salute our employees for their execution of the vision established two years ago.”

The Company’s cash position is $26.6 million at June 30, 2006, an increase of $8.1 million from last fiscal year. Cash effects associated with the income tax expenses reflected in the current fiscal year were minimal due to the utilization of net operating loss carry forwards.

- MORE -

Hyaluronan Division

Net sales from the Hyaluronan Division for the fourth quarter were a record $5.5 million, an increase of 27% from the $4.3 million reported in the same quarter last year. Net sales for fiscal year 2006 were also a record at $20.2 million compared to $18.5 million a year ago, an increase of $1.7 million or 9%. Growth in both the quarter and the fiscal year resulted from higher sales to orthopedic customers and increased revenue from product development.

The Division reported operating income of $1,737,000 for the fourth quarter compared to operating income of $293,000 in the fourth quarter of fiscal year 2005. Operating income of $5,284,000 was reported for fiscal year 2006 compared to operating income of $3,485,000 last fiscal year.

“Record sales in the fourth quarter drove operating income to a record level,” said Dennis J. Allingham, President & CEO. “Operating income of 32% for the quarter and 26% for the fiscal year is indicative of the leverage in this business from higher sales levels.”

Oral Restorative Division

Net sales from the Oral Restorative Division for the quarter were a record $12.2 million, an increase of 15% from the $10.6 million recorded in the fourth quarter last year. Net sales for fiscal year 2006 were a record $42.9 million compared to $37.2 million in fiscal year 2005, an increase of 16%. Domestic sales were especially strong with a 23% increase for the fourth quarter and a 22% increase for the fiscal year. International sales were up 5% for the fourth quarter and 8% for the fiscal year. Foreign currency translation comparisons decreased fiscal 2006 sales by $422,000 compared to fiscal 2005.

The Division reported operating income of $1,943,000 for the fourth quarter compared to operating income of $1,818,000 in the fourth quarter of fiscal year 2005. Operating income of $5,592,000 was reported for the fiscal year compared to operating income of $4,585,000 in fiscal year 2005.

“Strong domestic sales, driven by the contribution from the Prima™ Implant System, produced record operating income,” said Dennis J. Allingham, President & CEO. “We continue to see this product line penetrate the market and clinical performance has been extremely encouraging.”

Outlook

The Company expects fiscal year 2007 sales of $70 to $72 million, which represents an increase of 11 to 14 percent over fiscal year 2006.

Growth is expected to again be driven by the Oral Restorative Division in fiscal year 2007, particularly in the domestic market as we accelerate the rate of sales force expansion. We anticipate improved growth in our international markets in fiscal 2007 with the launch of the Prima™ Implant System throughout the fiscal year. The pattern of growth for the Hyaluronan Division is expected to be similar to fiscal year 2006, i.e., occurring later in the fiscal year.

The Company expects continued improvement in profitability with a 19 to 27 percent increase in net income. Fiscal 2007 earnings per share are expected to be $.61 to $.65 per diluted share, reported as if fully taxed at 38.5%. The Company noted that fiscal year 2007 guidance reflects stock option expenses of $1.1 million.

- MORE -

The Company expects sales of $14.8 to $15.2 million in the first quarter of fiscal year 2007 with earnings per diluted share of $.07 to $.09, reported as if fully-taxed at 38.5%. This guidance reflects stock option expense of $266,000.

Disclosure of Pro-Forma Information

Lifecore reports its financial results in accordance with generally accepted accounting principles (“GAAP”) and additionally on a non-GAAP basis referred to as pro-forma. These pro-forma measures are not in accordance with, nor are they a substitute for, GAAP measures and may not be consistent with the presentation used by other companies. Lifecore uses the pro-forma financial measures to evaluate and manage the Company’s operations. Lifecore is providing this information to investors and analysts to facilitate performance of additional financial analysis, because it is consistent with financial models and estimates published by securities analysts, and because Lifecore’s management also evaluates the Company’s performance on this basis. See the discussion below and the reconciliation of GAAP net income to pro-forma net income information for an explanation and quantification of amounts excluded from pro-forma basis results.

Reconciliation of GAAP Net Income to Pro-Forma Net Income Information

As a result of the Company’s profitability and outlook for future periods, the Company concluded in the fourth quarter of fiscal year 2005 that it is likely to have sufficient taxable income in future periods to utilize its net operating loss (“NOL”) carry forwards. Prior to this quarter, these tax assets were reserved on the Company’s balance sheet in the form of a deferred tax valuation allowance. In accordance with GAAP, the Company released $11.9 million of this valuation reserve to fiscal 2005 fourth quarter and year-end net income. Accordingly, the Company now reports its net income as if fully taxed, using an effective tax rate of 39.7% for the fourth quarter and 38.4% for fiscal year 2006. The Company will realize the cash benefit of these NOL’s through lower actual taxes paid in future periods until the tax carry forwards are exhausted.

Pro-forma fiscal 2005 fourth quarter and fiscal year results assume comparable effective income tax rates of 33.3%.

Included in fiscal 2006 fourth quarter and year-end results are charges of $211,000 and $844,000, respectively, for expensing stock options pursuant to SFAS No. 123R, “Share-Based Payment”, which became effective July 1, 2005. The pro-forma results add back the expense to improve comparability between periods as stock option expense was not required to be recorded in last year’s results.

- MORE -

A reconciliation of GAAP net income to pro-forma net income follows:

Lifecore Biomedical, Inc.
Reconciliation of GAAP Net Income to Pro-Forma Net Income Information
(Unaudited)

	Three Months Ended					Twelve Months Ended
	June 30,					June 30,
	2006		2005			2006		2005
	Pro-Forma		Pro-Forma			Pro-Forma		Pro-Forma
Net income, as reported	$	2,411,000	$	11,744,000		$	7,040,000	$	17,511,000
Less: Tax benefit from release of Valuation Allowance, net		—		(10,205,000	)		—		(11,922,000	)
Add: Remove effect of stock option expense		211,000		—			844,000		—
Pro-forma net income	$	2,622,000	$	1,539,000		$	7,884,000	$	5,589,000
Pro-forma net income per share
Basic	$	0.20	$	0.12		$	0.60	$	0.43
Diluted	$	0.19	$	0.11		$	0.58	$	0.42
Weighted average shares outstanding
Basic		13,195,771		13,028,016			13,149,611		12,974,730
Diluted		13,652,548		13,544,347			13,561,852		13,344,642

- MORE -

Conference Call

As previously announced, the Company will host a conference call today at 3:45 p.m. Central Time to discuss fourth quarter and year-end results. A live web cast of the call is available through the Company’s website at www.lifecore.com. After selecting the INVESTOR INFO tab, select CALENDAR OF EVENTS from the INVESTOR INFO & RESEARCH menu at the right side of the page and follow the instructions for participation. A replay of the web cast will be available shortly after completion of the call. To select the archived replay, select AUDIO ARCHIVES from the INVESTOR INFO & RESEARCH tools menu at the right side of the screen. The conference call will also be available at www.earnings.com.

The conference call may include forward-looking statements. See the cautionary information about such statements in the “Safe-Harbor Statement” section below.

Safe-Harbor Statement

Certain statements in this release regarding Lifecore’s anticipated future sales and financial results are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Numerous risks and uncertainties may affect whether such results are actually achieved. These include the timing of orders from customers, continued market acceptance of the Company’s products, rate of sales force expansion, timing of regulatory approvals, success of new product development efforts, the likelihood and timing of the return of the Company’s adhesion prevention product to the market, and other factors. These risks and uncertainties are more fully described in the Company’s Annual Report on Form 10-K, including Exhibit 99.1, for the fiscal year ending June 30, 2005, and other, more recent filings. Actual results may differ materially from anticipated results.

About Lifecore Biomedical

Lifecore Biomedical develops, manufactures, and markets biomaterials and medical devices for use in various surgical markets.

News and general information are available through the Company’s website at www.lifecore.com or by telephone at 952-368-4300.

Contact:

Dennis J. Allingham, President and CEO
David M. Noel, Vice President of Finance and CFO

- MORE -

Lifecore Biomedical, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

	June 30,		June 30,
	2006		2005
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	26,638,000	$	18,508,000
Accounts receivable		12,564,000		10,171,000
Inventories		12,217,000		9,456,000
Deferred income taxes, net		4,865,000		4,190,000
Prepaid expense		1,084,000		780,000
Total current assets		57,368,000		43,105,000
PROPERTY, PLANT AND EQUIPMENT, NET		23,250,000		23,189,000
LONG-TERM INVENTORY		1,406,000		2,409,000
DEFERRED INCOME TAXES, NET		1,694,000		6,062,000
OTHER ASSETS		5,520,000		5,101,000
	$	89,238,000	$	79,866,000
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities	$	6,898,000	$	6,916,000
Long-term obligations		4,804,000		5,089,000
Shareholders’ equity		77,536,000		67,861,000
	$	89,238,000	$	79,866,000

- MORE -

Lifecore Biomedical, Inc.
Consolidated Statements of Operations
(Unaudited)

	Three Months Ended						Twelve Months Ended
	June 30,						June 30,
	2006			2005			2006			2005
Net sales	$	17,688,000		$	14,925,000		$	63,097,000		$	55,695,000
Cost of goods sold		6,493,000			6,249,000			23,892,000			22,387,000
Gross profit		11,195,000			8,676,000			39,205,000			33,308,000
Operating expenses
Research and development		936,000			958,000			3,814,000			4,212,000
Marketing and sales		4,793,000			4,138,000			17,454,000			14,851,000
General and administrative		1,786,000			1,469,000			7,061,000			6,175,000
		7,515,000			6,565,000			28,329,000			25,238,000
Operating income		3,680,000			2,111,000			10,876,000			8,070,000
Other income (expense)
Interest income		258,000			108,000			753,000			217,000
Interest expense		(70,000	)		(59,000	)		(251,000	)		(280,000	)
Bond retirement expense		—			—			—			(290,000	)
Currency transaction gains (losses)		98,000			(21,000	)		25,000			299,000
Other		31,000			117,000			17,000			366,000
		317,000			145,000			544,000			312,000
Income before income tax (benefit)		3,997,000			2,256,000			11,420,000			8,382,000
Income tax expense (benefit)		1,586,000			(9,488,000	)(2)		4,380,000			(9,129,000	)(3)
Net Income	$	2,411,000	(1)	$	11,744,000	(2)	$	7,040,000	(1)	$	17,511,000	(3)
Net income per share
Basic	$	0.18		$	0.90	(2)	$	0.54		$	1.35	(3)
Diluted	$	0.18		$	0.87	(2)	$	0.52		$	1.31	(3)
Weighted average shares outstanding
Basic		13,195,771			13,028,016			13,149,611			12,974,730
Diluted		13,652,548			13,544,347			13,561,852			13,344,642

(1)	- Results for the current fiscal year include the effect of adopting SFAS 123R to expense stock options, which reduced net income by $211,000 and $844,000 for the fourth quarter and twelve-month period, respectively.
(2)	- Net income for the quarter was increased by a tax benefit resulting from the release of the valuation allowance of $11,922,000 or $.88 per diluted share and includes income tax expense of $751,000 applicable to fourth quarter operations and $1,717,000 to adjust tax expense for the first nine months to an annual effective rate of 33.3%.
(3)	- Net income for the year was increased by a tax benefit resulting from the release of the valuation allowance of $11,922,000 or $.89 per diluted share and reported income tax expense was 33.3%.

- MORE -

Lifecore Biomedical, Inc.
Divisional Statements of Operations
Three Months Ended June 30,
(Unaudited)

	Hyaluronan Division				Oral Restorative Division				Consolidated
	2006		2005		2006		2005		2006		2005
Net sales	$	5,512,000	$	4,324,000	$	12,176,000	$	10,601,000	$	17,688,000	$	14,925,000
Cost of goods sold		2,346,000		2,642,000		4,147,000		3,607,000		6,493,000		6,249,000
Gross profit		3,166,000		1,682,000		8,029,000		6,994,000		11,195,000		8,676,000
Operating expenses
Research and development		573,000		622,000		363,000		336,000		936,000		958,000
Marketing and sales		237,000		137,000		4,556,000		4,001,000		4,793,000		4,138,000
General and administrative		619,000		630,000		1,167,000		839,000		1,786,000		1,469,000
		1,429,000		1,389,000		6,086,000		5,176,000		7,515,000		6,565,000
Operating income	$	1,737,000	$	293,000	$	1,943,000	$	1,818,000	$	3,680,000	$	2,111,000

Lifecore Biomedical, Inc.
Divisional Statements of Operations
Twelve Months Ended June 30,
(Unaudited)

	Hyaluronan Division				Oral Restorative Division				Consolidated
	2006		2005		2006		2005		2006		2005
Net sales	$	20,151,000	$	18,528,000	$	42,946,000	$	37,167,000	$	63,097,000	$	55,695,000
Cost of goods sold		9,204,000		9,159,000		14,688,000		13,228,000		23,892,000		22,387,000
Gross profit		10,947,000		9,369,000		28,258,000		23,939,000		39,205,000		33,308,000
Operating expenses
Research and development		2,301,000		3,073,000		1,513,000		1,139,000		3,814,000		4,212,000
Marketing and sales		670,000		512,000		16,784,000		14,339,000		17,454,000		14,851,000
General and administrative		2,692,000		2,299,000		4,369,000		3,876,000		7,061,000		6,175,000
		5,663,000		5,884,000		22,666,000		19,354,000		28,329,000		25,238,000
Operating income	$	5,284,000	$	3,485,000	$	5,592,000	$	4,585,000	$	10,876,000	$	8,070,000

- END -